Post-earnings recap
Reported
Tue, May 3, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Kymera Therapeutics reported a larger-than-expected loss per share, which contributed to a significant drop in stock price. The lack of revenue figures and guidance left investors uncertain about the company's future. The 23.98% decline in stock price reflects market disappointment and concerns about the company's path to profitability.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.71 | N/A | -5.97% |
| Revenue | N/A | N/A | N/A |
Management expressed caution regarding future performance. They highlighted ongoing challenges but did not provide specific guidance for the next quarter.
Management did not provide specific revenue guidance for the upcoming quarters.
The company acknowledged challenges in achieving profitability in the near term.